An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Levetiracetam (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms ILiAD
- 15 Oct 2018 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.
- 15 Oct 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.
- 09 Apr 2018 New trial record